Sumitovant Keeping Sumitomo Dainippon-Acquired Roivant Companies On Track

Scrip spoke with Sumitovant CEO Myrtle Potter about short- and long-term goals for the portfolio of five companies, including Myovant, Urovant and Enzyvant with potential near-term approvals.

Young lady running on a rural road during sunset
Sumitovant's subsidiaries never broke their stride in transition to SDP • Source: Shutterstock

Sumitovant Biopharma Ltd. didn’t just hit the ground running when it launched as a subsidiary of Sumitomo Dainippon Pharma Co. Ltd. (DSP) at the end of 2019, and as the parent company for five companies acquired for $3bn from Roivant Sciences Inc. – it never broke its stride, since the portfolio was seamlessly integrated into DSP after the deal closed, according to Sumitovant CEO Myrtle Potter.

Potter noted that “oftentimes, two organizations come together … and it takes companies two or three years to go through...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.